Emisión de acciones de suscripción de RiverFort
Sareum Holdings plc
("sareo" o la "Empresa")
Emisión de acciones de suscripción de RiverFort
Cambridge, Reino Unido, 19 Abril 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has issued 3,000,000 new Ordinary Shares in the capital of the Company to RiverFort Global Opportunities PCC Ltd ("fuerte del río"), in accordance with the terms of the Facility as announced on 3 August 2023.
The Company has an outstanding balance of circa £0.22 million under the Facility. Any balances pursuant to the Facility are not due for repayment until August 2025 (the "Fecha de vencimiento") and the Company expects to settle all balances by the issuance of Subscription Shares prior to the Maturity Date.
As noted in Sareum's announcement of 28 March 2024, the Company does not intend to make any further withdrawals pursuant to the Facility with RiverFort.
Admisión y derechos totales de voto
Application has been made to the London Stock Exchange plc for the admission of 3,000,000 new Ordinary Shares to trading on AIM ("Admisiones"). It is expected that Admission will occur at 8.00 a.m. (London time) on or around Wednesday 24 April 2024.
Immediately following Admission, the total number of Ordinary Shares in issue will be 104,578,309 and the total number of voting rights will therefore be 104,578,309, and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Terms and definitions used in this announcement shall have the same meaning as ascribed to them in the Company's announcement dated 3 August 2023, unless otherwise stated.
Para mayor información:
Sareum Holdings plc Tim Mitchell, director general Lauren Williams, jefa de relaciones con inversores
| 01223 497700 |
Strand Hanson Limited (Asesor designado) James Danza / James Bellman
| 020 7409 3494 |
Peel Hunt LLP (empresa conjunta Broker) | 020 7418 8900 |
James Steel/Patrick Birkholm
| |
Hybridan LLP (empresa conjunta Broker) claire noyce
| 020 3764 2341 |
ICR Consilium (RR.PP. financieras) Jessica Hodgson / Davide Salvi / Kumail Waljee | 0203 709 5700 |
Acerca de Sareum
Sareum Holdings (AIM:SAR) es una empresa de biotecnología en etapa clínica que desarrolla inhibidores de quinasa de próxima generación para enfermedades autoinmunes y cáncer.
La empresa se centra en desarrollar moléculas pequeñas de próxima generación que modifiquen la actividad de la familia de quinasas JAK y tengan el mejor potencial de su clase. Su principal candidato, SDC-1801, inhibe simultáneamente TYK2 y JAK1. SDC-1801 es un tratamiento potencial para una variedad de enfermedades autoinmunes y ha entrado en la fase 1a/b de desarrollo clínico con un enfoque inicial en la psoriasis.
Sareum también está desarrollando SDC-1802, un inhibidor de TYK2/JAK1 con una aplicación potencial para la inmunoterapia contra el cáncer.
Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.